1,332
Views
0
CrossRef citations to date
0
Altmetric
Lecture

Ellen Grass Memorial Lecture: Clinical Neurophysiology in the Treatment of Disease

, M.D.,FACNS
Pages 203-212 | Received 04 Sep 2018, Accepted 11 Sep 2018, Published online: 12 Dec 2018

References

  • Amato AA. 2018. Myasthenia gravis and other diseases of the neuromuscular junction. In Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison’s principles of internal medicine. 20th ed. New York (NY): McGraw-Hill.
  • Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. 2007. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 48:1308–17.
  • Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, Laroche SM, Riviello JJ, Shutter L, Sperling MR, et al. 2012. Guidelines for the Evaluation and Management of Status Epilepticus. Neurocritical Care. 17:3–23.
  • Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H, et al. 2017. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 16:189–99.
  • CCEMRC. Critical care EEG monitoirng research consortium [online]. [accessed 2018 Sep 2. https://www.acns.org/research/critical-care-eeg-monitoring-research-consortium-ccemrc.
  • Claassen J, Mayer SA, Kowalski RG, Emerson RG, Hirsch LJ. 2004. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology. 62:1743–48.
  • Epilepticus WGoS. 1993. Treatment of convulsive status epilepticus: recommendations of the epilepsy foundation of america’s working group on status epilepticus. JAMA. 270:854–59.
  • Guideline ACNS. 2006. 9B: guidelines on Visual Evoked Potentials. J Clin Neurophysiol. 23:138–56.
  • Halford JJ, Arain A, Kalamangalam GP, LaRoche SM, Leonardo B, Basha M, Azar NJ, Kutluay E, Martz GU, Bethany WJ, et al. 2017. Characteristics of EEG interpreters associated with higher interrater agreement. J Clin Neurophysiol. 34:168–73.
  • Halford JJ, Shiau D, Desrochers JA, Kolls BJ, Dean BC, Waters CG, Azar NJ, Haas KF, Kutluay E, Martz GU, et al. 2015. Inter-rater agreement on identification of electrographic seizures and periodic discharges in ICU EEG recordings. Clin Neurophysiol. 126:1661–69.
  • Herman ST, Abend NS, Bleck TP, Chapman KE, Drislane FW, Emerson RG, Gerard EE, Hahn CD, Husain AM, Kaplan PW, et al. 2015. Consensus statement on continuous EEG in critically ill adults and children, part II: personnel, technical specifications and clinical practice. J Clin Neurophysiol. 32:96–108.
  • Husain AM. 2015. Lacosamide in status epilepticus: update on the TRENdS study. Epilepsy Behav. 49:337–39.
  • Husain AM, Hayes S, Young M, Shah D. 2009. Visual evoked potentials with CRT and LCD monitors. When Newer Is Not Better. 72:162–64.
  • Husain AM, Lee JW, Kolls BJ, Hirsch LJ, Halford JJ, Gupta PK, Minazad Y, Jones JM, LaRoche SM, Herman ST, et al. 2018. Randomized trial of lacosamide versus fosphenytoin for nonconvulsive seizures. Ann Neurol. 83:1174–85.
  • Liščič RM, Brecelj J. 2004. Visual evoked potentials in multiple sclerosis patients treated with interferon beta-1a. Croat Med J. 45:323–27.
  • Lowenstein DH, Bleck T, Macdonald RL. 1999. It’s Time to Revise the Definition of Status Epilepticus. Epilepsia. 40:120–22.
  • Mayeux R. 2004. Biomarkers: potential uses and limitations. NeuroRX. 1:182–88.
  • Meriggioli MN, Rowin J. 2003. Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial. J Clin Neurophysiol. 20:382–85.
  • Paty DW, Li DKB. 1993. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis. II MRI analysis results of a multicenter, randomized, double‐blind, placebo‐controlled trial. Neurology. 43(4):662–7.
  • Pitt M. 2018. Neurophysiological assessment of abnormalities of the neuromuscular junction in children. Int J Mol Sci. 19:624.
  • Rudick RA, Mi S, Sandrock AW. 2008. LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence. Expert Opin Biol Ther. 8:1561–70.
  • Sanders DB, Massey JM. 2017. Does change in neuromuscular jitter predict or correlate with clinical change in MG?. Muscle Nerve. 56:45–50.
  • Sherwin CMT, Fukuda T, Brunner HI, Goebel J, Vinks AA. 2011. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 50:1–24.
  • Swisher CB, Shah D, Sinha SR, Husain AM. 2015. Baseline EEG pattern on continuous ICU EEG monitoring and incidence of seizures. J Clin Neurophysiol. 32:147–51.
  • Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, et al. 2018. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17:162–73.
  • Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein DH. 2015. A definition and classification of status epilepticus – report of the ILAE task force on classification of status epilepticus. Epilepsia. 56:1515–23.
  • Tsuneishi S, Casaer P. 1997. Stepwise decrease in VEP latencies and the process of myelination in the human visual pathway. Brain Dev. 19:547–51.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.